Abstract: This invention relates to pharmaceutical compositions comprising anaerobe-selective antibacterial agents which are substituted or unsubstituted 1,12-dodecanedioic peroxy acids, or their pharmaceutically-acceptable salts or esters. The pharmaceutical compositions of the present invention are especially suitable for oral administration in the form of mouth rinses and toothpastes. These anaerobe-selective antibacterial compositions are useful for treating or preventing anaerobic bacterial infections, especially diseases of the oral cavity, in humans or lower animals.The present invention further relates to a method for treating or preventing anaerobic bacterial infections such as acne, and especially diseases of the oral cavity such as gingivitis and periodontal disease, in humans or lower animals.

Abstract: The present invention involves compounds of the class of acylphosphorotriamides and methods for altering the blood plasma lipid content of mammals which comprises systemically administering to mammals an effective but nontoxic amount of a composition comprising such compounds.

Abstract: The invention involves a sustained release pharmaceutical capsule for oral administration comprising, in a capsule shell, a particulate mixture comprising an active drug ingredient which is a weak acid, neutral, or a weak base, polyvinylpyrrolidone, and carboxyvinylpolymer.

Abstract: The invention involves a combination sustained release/rapid release pharmaceutical capsule for oral administration of nitrofurantoin comprising, in a capsule shell, a first layer of a first particulate mixture comprising nitrofurantoin, polyvinylpyrrolidone and carboxyvinylpolymer; and a second layer of a second particulate mixture comprising macrocrystalline nitrofurantoin.

Abstract: A method for treating or preventing osteoporosis utilizing a cyclic regimen comprising alternating for two or more cycles the administration of a bone resorption inhibiting polyphosphonate and a no treatment (rest) period. Further disclosed is a kit for use in implementing this method of treatment.

Abstract: The present invention involves compounds of the class of imidazo[4,5-f]quinolines and methods for enhancing the immune response system of mammals which comprises systemically administering to mammals having a depressed immune function an effective but nontoxic amount of a composition comprising such a compound.

Abstract: The present invention provides for a process for transforming a substantially continuous web of substantially planar, deformable material having an indefinite length, a first surface, and a second surface into a formed material. The material has a transformation temperature range. The process comprises the following steps:(a) The web of material is provided on a forming structure with the first surface of the web of material proximate a forming surface of the forming structure. The forming surface moves in a direction of the length of the web of material and carries the web of material in that direction.(b) A liquid stream is applied to the second surface of the web of material. The liquid stream has sufficient force and mass flux to cause the web of material to be deformed toward the forming surface, such that the material acquires a substantial three-dimensional conformation.

Abstract: The present invention involves compounds of the class of acylphosphorotriamides and methods for altering the blood plasma lipid content of mammals which comprises systemically administering to mammals an effective but nontoxic amount of a composition comprising such compounds.

Abstract: A furazolidone dosage unit form comprises the drug furazolidone, a sustained release matrix, and an enteric coating.

Abstract: Certain 5-phenyl-2-furoic acid hydrazides of the formula: ##STR1## wherein X represents 4-chloro, 4-fluoro, 3-trifluoromethyl or hydrogen, R.sub.1 represents hydrogen or methyl, R.sub.2 represents acetyl, isopropyl or methyl, and R.sub.1 and R.sub.2 taken together represent isopropylidene or 4-pyridinylmethylene are useful as anti-inflammatory agents.

Abstract: The invention involves compositions useful for treating certain malignant tumors with the compound ethyl 4-hydroxy-2-[(5-morpholinomethyl-2-oxo)-3-oxazolidinyliminomethyl]furo[2,3 -b]pyridine-5-carboxylate (Compound I) or its pharmaceutically acceptable salts or hydrates.

Abstract: The present invention provides a layered absorbent structure, the structure having an upper surface and a lower surface. The structure comprises:(a) n webs of fibrous material, n being an integer of two or more. The webs are layered such that there is an uppermost web, a lowermost web, n-2 intermediate webs, and n-1 interfaces of two opposed adjacent contacting surfaces of adjacent webs. Each of the interfaces has a surface area.(b) Absorbent particles forming a discontinuous layer at one or more of the interfaces.The opposed adjacent contacting surfaces at each interface where particles are present are substantially entirely frangibly bonded by fiber entanglement between the contacting surfaces. The particles are immobilized at said interface(s) substantially entirely by fiber entrapment.

Abstract: The present invention provides a layered absorbent structure, the structure having an upper surface and a lower surface. The structure comprises:(a) n webs of fibrous material, n being an integer of two or more. The webs are layered such that there is an uppermost web, a lowermost web, n-2 intermediate webs, and n-1 interfaces of two opposed adjacent contacting surfaces of adjacent webs. Each of the interfaces has a surface area.(b) Absorbent particles forming a discontinuous layer at one or more of the interfaces.The opposed adjacent contacting surfaces at each interface where particles are present are substantially entirely frangibly bonded by fiber entanglement between the contacting surfaces. The particles are immobilized at said interface(s) substantially entirely by fiber entrapment.

Abstract: Dantrolene sodium is useful as a cardiac antiarrhythmic agent in hypothermic and normothermic warm-blooded animals.

Abstract: A method is presented for using scented oils to provide odor to a container of a product having a constituent incompatible with the scented oils. An aqueous emulsion which comprises from about 4% to about 70% of a water-emulsifiable or water-soluble polymer, from about 5% to about 80% of scented oils, and from about 6% to about 80% of water is prepared. The aqueous emulsion is dried whereby the scented oils are entrapped within the matrix of the polymer. The polymer matrix is included in the container with the product whereby the scented oils are protected by the polymer matrix from degradation by the incompatible constituent and diffuse from the polymer matrix over a period of time.

Abstract: New thiocyanatoquinoxaline compounds useful as immunomodulating agents which have the general formula: ##STR1## wherein R is hydrogen, methyl or 5-thiocyanato-2-furanyl; R.sub.1 is hydrogen, methyl or 2-furanyl; or R and R.sub.1 taken together completes a cyclohexyl ring.

Abstract: A process for making a nonwoven fabric barrier layer that comprises simultaneously ring-rolling to a desired basis weight at least two adjacent plies of hydrophobic microfine fiber webs. The adjacent plies prior to ring-rolling have a cumulative basis weight of from about 1.1 to about 4 times the desired basis weight.

Abstract: Thermoplastic elastomeric films comprise from about 40% to about 80% of an elastomeric block copolymer and from about 20% to about 60% of an ethylene-vinyl acetate copolymer. The block copolymer has at least two monoalkenyl arene polymer end blocks and at least one elastomeric conjugated diene midblock. The monoalkenyl arene polymer blocks comprise from about 8% to about 55% by weight of the block copolymer. The block copolymer has a melt index of less than about 10. The ethylene-vinyl acetate copolymer comprises from about 22% to about 33% vinyl acetate and has a melt index of less than about 0.6. The film is from about 0.03 mm to about 0.15 mm in thickness.

Abstract: Antibacterial cleansing products comprise from about 0.001% to about 50% of a bisbiguanide bactericidal substance, and from about 0.05% to about 99% of specific nonionic surfactants.

Abstract: A process for the recovery of a water soluble alcohol from an aqueous mixture of the alcohol comprises incorporating in the mixture at least about 0.5% of a base selected from the group consisting of ammonium or alkali or alkaline metal hydroxide, ammonium or an alkali or alkaline metal carbonate or mixtures thereof; and at least about 0.2% of an electrolyte. The aqueous-alcohol mixture separates into two immiscible layers, and the layers are separated.